BioSpace News Archive

Genetown

Kala Pharmaceuticals Announces Statistically Significant Results for Primary and Key Secondary Endpoints in STRIDE 3 Clinical Trial Evaluating EYSUVIS™ for Signs and Symptoms of Dry Eye Disease

STRIDE 3 Met Both Prespecified Primary Efficacy Endpoints, Ocular Discomfort Severity in the Overall ITT Population and in ITT Patients with More Severe Baseline Discomfort

March 9, 2020
·
10 min read
Deals

Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2020

The board of directors of Medtronic plc on Friday, March 6, 2020, approved the fiscal year 2020 fourth quarter cash dividend of $0.54 per ordinary share, representing an 8 percent increase over the prior year.

March 9, 2020
·
1 min read
Policy

Emerald Health Therapeutics, Pure Sunfarms, and Village Farms Complete Settlement of All Disputes

Emerald Health Therapeutics, Inc. announced that, further to its news release dated March 3, 2020, all transactions contemplated by the settlement agreement among Emerald, Village Farms International, Inc. and Pure Sunfarms Corp. regarding disputes between the Parties have been completed.

March 9, 2020
·
3 min read
Deals

Emerald Health Therapeutics Signs LOI with Sigma Analytical ServicesEmerald agrees to sell Avalite analytical testing business and establish a preferred testing services relationship

Emerald Health Therapeutics, Inc. has signed a letter of intent under which Sigma Analytical Services Inc., a full-service GMP-compliant testing laboratory for cannabis, hemp, and derived products, may acquire Emerald’s Avalite cannabis analytical testing operation.

March 9, 2020
·
5 min read
Policy

Athenex Announces FDA Acceptance for Filing of U.S. NDA for Tirbanibulin Ointment in Actinic KeratosisPDUFA date of December 30, 2020

Athenex, Inc. announced that the U.S. Food and Drug Administration has completed its filing review and determined that the Company’s New Drug Application for tirbanibulin ointment for the treatment of actinic keratosis is sufficiently complete to permit a substantive review.

March 9, 2020
·
5 min read
Business

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

Key BXCL501 data readouts expected in mid-2020 – including results from the SERENITY program and the Phase 1b/2 TRANQUILITY trial in geriatric dementia

March 9, 2020
·
13 min read
Policy

Canadians suffering from diarrhea-predominant Irritable Bowel Syndrome (IBS-D) have a new clinically proven option approved by Health Canada

Canada has one of the highest prevalence rates of IBS in the world – estimated at 18% compared to 11% globally.

March 9, 2020
·
3 min read
Bio NC

RedHill Biopharma Announces U.S. Commercial Launch of Talicia® for H. pylori Infection

Talicia® is the first and only FDA-approved rifabutin-based therapy for treatment of H. pylori infection designed as a first-line option to address the high and growing H. pylori resistance to clarithromycin

March 9, 2020
·
11 min read
Business

Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2020 Financial Results

Global Cord Blood Corporation announced that it plans to release unaudited financial results for the third quarter and first nine months of fiscal year 2020 on Wednesday, March 11, 2020, after the market close.

March 9, 2020
·
2 min read
Deals

Apttus and HighPoint, an IQVIA Company, Expand Quote-to-Cash System Integrator (SI) Partnership Across the Globe

Apttus and HighPoint, an IQVIA company, Have Partnered To Bring Digital Transformation To Tech Projects Across the Healthcare and Life Sciences Industry

March 9, 2020
·
2 min read